NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has announced that its Phase IIA clinical trial of NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus disease in the Democratic Republic of Congo (DRC) is advancing, with progression to Phase IIB expected after the initial phase concludes. Enrollment began on September 23, 2026, and approximately 20 patients are expected to participate in Phase IIA, which is designed to evaluate dosing regimens based on disease severity. The primary endpoint is 28-day survival, and the initial phase will end once the final enrolled patient completes the observation period.
The announcement holds significant implications because the ongoing Ebola Bundibugyo outbreak in the DRC has resulted in more than 10,000 confirmed cases and approximately 4,900 deaths. Currently, no treatments or vaccines are approved specifically for Ebola Bundibugyo, and according to NanoViricides, NV-387 Oral Gummies is the only oral drug candidate undergoing clinical evaluation for the disease. An oral antiviral could be particularly valuable in outbreak settings where healthcare infrastructure is limited, as it may be easier to administer than injectable therapies.
NanoViricides is also evaluating NV-387 Oral Gummies in a separate Phase II clinical trial for mpox in the DRC, further testing the drug's broad-spectrum potential. The company's lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. For investors, the progress of the Ebola trial represents a key milestone in the clinical development of NV-387 and could enhance the company's profile in the antiviral space. More information about NanoViricides, Inc. (NYSE American: NNVC) is available through its investor relations page, and the full press release can be viewed at https://ibn.fm/JJ69W.
The company's broader pipeline includes NV-CoV-2 and NV-CoV-2-R for COVID-19, as well as drugs in development for oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology is based on the TheraCour nanomedicine technology, and the company holds a worldwide exclusive perpetual license for several drugs targeting specific human viral diseases. As with any drug development effort, there can be no assurance that the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
For ongoing updates on NNVC, the company maintains a newsroom at https://ibn.fm/NNVC. The announcement was distributed through BioMedWire, a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform also offers editorial syndication to 5,000+ outlets and social media distribution to millions of followers.
